Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.

NCT03838159 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT03838159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03838159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Neo-adjuvant Chemo/Immunotherapy Versus Chemotherapy Alone for the Treatment of Locally Advanced and Potentially Resectable Non-small Cell Lung Cancer (NSCLC) Patients.
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 15, 2019
Completion date
November 30, 2028
Enrollment
90 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer